Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 67.98
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Data is available to registered users only
Target Price
The average target price of BBIO is 98 and suggests 44% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Data is available to registered users only
Buy
Sell